CritiTech Announces
New Board Director
September 2, 2005
FOR IMMEDIATE RELEASE
Lawrence, Kan. - CritiTech today announced that Dr. Joseph
A. Fix has joined its Board of Directors. Dr. Fix has an extensive
drug delivery and pharmaceutical industry background in addition
to his experience in working in the micro and nanoparticle
pharmaceutical arena. Dr. Fix has over 25 years experience
in drug delivery, product development, operations, business
development, contract negotiations, and regulatory and quality
systems.
“We are very excited that Joe has agreed
to join CritiTech’s Board at this pivotal stage in the
company’s development. His broad base of experience
and expertise will be invaluable to the company as we progress
further into the commercialization stage in our business,”
said CEO and President Sam Campbell.
Dr. Fix has held a number of executive positions
in the pharmaceutical industry. Most recently he was President
and COO of Cydex, Inc. Previously he was EVP and COO of NanoSystems,
Inc., a unit of Elan Corporation. Before joining Elan, he
was President and CTO of Yamanouchi Pharma Technologies and
Associate Director of Biological Sciences for ALZA Corporation.
He began his career with Merck and Company, advancing to Associate
Director, Biopharmaceutics for the INTERx research division.
Dr. Fix holds a Ph.D. in neurophysiology from
the University of Kansas and an MBA from Pepperdine University.
He has held adjunct faculty positions at the University of
Southern California, Purdue University, and the University
of Kansas. He is the author of numerous publications and holds
17 patents in the drug delivery area.
CritiTech provides critical drug delivery and
development technology for the pharmaceutical industry. CritiTech
produces fine-particle pharmaceuticals including nanoparticle
pharmaceuticals using patented technologies developed at the
University of Kansas. The processes use compressed carbon
dioxide as the processing medium to produce relatively residue-free
and uniform drug microparticles and coatings.
The pharmaceutical industry has exhibited substantial
interest in processes that produce improved formulations using
nanoparticulate drugs in order to extend the patent life of
an existing drug or to enable the delivery of a poorly soluble
compound. CritiTech has also successfully used its proprietary
technology to coat medicinal agents either on small particle
drugs for improved drug delivery or as a thin film on implantable
medical devices such as cardiac stents. The Nanotax™
ovarian cancer drug is the first drug to be announced under
the company’s drug development program.
|
